Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal

Recombinant Trypsinogen & ChymotrypsinogenPRP (synthetic recombinant)Positive

AI Analysis

Summary

Propanc Biopharma published an evaluation of recombinant trypsinogen and chymotrypsinogen in a peer-reviewed journal as part of its strategy to develop a new therapeutic drug class for chronic diseases.

Importance:2/10

Sentiment:

0.30

publicationpeer-reviewedrecombinant enzymestherapeutic developmentchronic disease

Related Companies

$PPCB

Read the original article

Published by GlobeNewswire Pharma on July 21, 2026 12:30 PM

Read Original